Human Cytomegalovirus can be dangerous for immunocompromised individuals and organ transplant recipients (
13). Reactivation occurs when the host cell's immune system is suppressed, and HCMV adapts to the host cell environment through viral transport mediators. Stress can trigger the reactivation of latent HCMV, inducing host immune responses through innate immune processes (
12,
14). These responses include inflammatory cytokines and natural killer (NK) cell responses, leading to an adaptive immune response. Human Cytomegalovirus expresses several gene products that alter regulatory proteins, non-coding RNA, and the host immune response (
15). To avoid detection, HCMV employs strategies to suppress both the innate and adaptive immune systems (
16). Several HCMV gene products, including US20, UL16, UL17, UL18, UL40, UL43, UL140, UL83, UL141, UL144, and UL148, have been identified as important for modulating NK cell activity. The products encoded by the UL16, UL17, UL40, UL140, and UL142 genes interact with the host human leukocyte antigen (HLA) class I antigen to regulate NK cell activity (
10). Human Cytomegalovirus downregulates HLA antigen expression and encodes proteins that inhibit peptide presentation by antigen-presenting cells (APCs), limiting T cell responses. It can also inhibit T cell proliferation and upregulate programmed cell death protein 1 (PD-1) receptor expression, causing apoptosis and reducing interleukin (IL)-2 and interferon gamma (IFN)-γ production (
14,
17). Tumor necrosis factor α (TNF-α) activates the HCMV immediate-early (IE) promoter in myeloid cells, but on its own, it is insufficient to reactivate latent HCMV. Nuclear factor kappa B (NF-κB) can interact with the HCMV IE promoter, enhancing viral replication. In undifferentiated pre-myelocytic cells, negative regulation of the promoter may allow the virus to persist (
9) (
Figure 1).